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Naproxen, an anti-inflammatory drug, exhibits poor aqueous solubility, which limits the pharmacological 
effects. The present work was carried out to study the effect of agglomeration on micromeritic properties 
and dissolution. Naproxen agglomerates were prepared by using a three solvents system composed of 
acetone (good solvent), water (non-solvent) and dichloromethane (bridging liquid). Differential Scanning 
Calorimetry (DSC) results showed no change in the drug after crystallization process. X-Ray Powder 
Diffraction (XRPD) studies showed the sharp peaks are present in the diffractograms of spherical 
agglomerates with minor reduction in height of the peaks. The residual solvents are largely below 
the tolerated limits in the agglomerates. Scanning Electronic Microscopy (SEM) studies showed that 
agglomerates were spherical in structure and formed by cluster of small crystals. The agglomerates 
exhibited improved solubility, dissolution rate and micromeritic properties compared to pure drug. 
Anti-inflammatory studies were conducted in Wistar strain male albino rats and naproxen agglomerates 
showed more significant activity than the pure drug.
Uniterms: Naproxen/micromeritic properties. Naproxen/spherical agglomerates/dissolution. Residual 
solvents. Ulcerogenic potential. Bridging liquid.
Naproxeno, fármaco anti-inflamatório, apresenta baixa solubilidade em água, o que limita os efeitos 
farmacológicos. O presente trabalho foi realizado para estudar o efeito da aglomeração nas propriedades 
micromeríticas e na dissolução. Aglomerados de naproxeno foram preparados por meio da utilização 
de sistema de três solventes composto de acetona (bom solvente), água (não-solvente) e diclorometano 
(líquido de ligação). A DSC não resulta mostrou nenhuma mudança na droga depois de processo de 
cristalização. Estudos de difração de Raios X do Pó (XRPD) mostraram picos agudos nos difratogramas 
de aglomerados esféricos, com redução mínima dea altura dos picos. Os solventes residuais estão 
amplamente abaixo dos limites tolerados nos aglomerados. Os estudos de Microscopia Eletrônica de 
Varredura (SEM) mostraram que esses aglomerados eram de estrutura esférica e formados por grupos 
de pequenos cristais. Os aglomerados apresentaram solubilidade, taxa de dissolução e propriedades 
micromeríticas aprimoradas em comparação com o fármaco puro. Estudos anti-inflamatórios foram 
conduzidos em ratos Wistar albinos masculinos e os aglomerados de naproxeno mostraram atividade 
mais significativa do que o fármaco puro. 
Unitermos: Naproxeno/propriedades micromeríticas. Naproxeno/aglomerados esféricos/dissolução. 
Solventes residuais. Potencial ulcerogênico. Líquido de ligação.
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INTRODUCTION
Recently the direct tablet compression method is 
frequently and preferably used for tablet manufacturing, 
since many processing steps (granulation, drying etc) are 
eliminated and in addition wet technology can not be used 
to moisture sensitivity agents (effervescent tablets) (Magh-
soodi et al., 2007). In the direct tabletting method, it is 
necessary to increase the flowability and compressibility of 
the bulk powder in order to retain a steady supply of powder 
mixture to the tabletting machine and sufficient mechanical 
strength of the compacted tablet. In addition to increasing 
the efficiency of the manufacturing process it is also impor-
tant to increase bioavailability of the drug by improving the 
solubility of the bulk drug powder. Spherical agglomeration 
is a novel method to increase the bioavailability of the drug 
that inherently has poor aqueous solubility. It is a multiple 
unit process in which crystallization, agglomeration and 
spheronization can be carried out simultaneously in one step 
(Kulkarni et al., 2002). The resultant crystals have charac-
teristic shape which dramatically improved the micromeritic 
properties such as flowability, packability and compress-
ibility so that direct tabletting or coating is possible without 
further processing (mixing, agglomeration, sieving).
Spherical agglomeration is a process of formation 
of aggregates of crystals held together by liquid bridges. 
The agglomerates are formed by agitating the crystals in a 
liquid suspension in presence of binding agent. The bridg-
ing liquid should be immiscible in the suspending medium, 
but capable of cementing the particles to be agglomerated. 
This technique can also be exploited to increase solubility, 
dissolution and hence bioavailability of poorly soluble 
drugs (Di Martino, 1999; Sano, 1987; Kawashima et al., 
1990). These modifications allow for the practice of more 
efficient manufacturing methods that could save time and 
reduces economic risk.
Naproxen is an anti-inflammatory drug which exhib-
its poor water solubility and unsuitable for direct tablet-
ting due to its poorly compressible properties, although 
strongly demanded in commercial production by direct 
tabletting. It exhibits poor flow, and a high tendency of 
adhesion. To improve the micromeritic properties, dis-
solution rate and bioavailability, spherical crystallization 
method is attempted.
MATERIAL AND METHODS
Naproxen was kindly provided by Divis labs, Hyder-
abad, India. Acetone and dichloromethane were purchased 
from Merck, Mumbai, India. All chemicals and buffers 
used were of analytical grade.
Selection of solvent proportions for spherical 
agglomeration
Ternary phase diagram of acetone, dichloromethane 
and water was constructed to select a suitable zone with 
appropriate ratio of three solvents for the preparation of 
spherical agglomerates.
Preparation of spherical agglomerates of 
naproxen
For spherical agglomeration of naproxen acetone 
was found to be suitable solvent due to its excellent solu-
bility and miscibility with dispersing water phase (poor 
solvent). Dichloromethane was chosen as bridging liquids 
because of its good wettability with the drug. Naproxen 
5 g was dissolved in 25 mL of acetone at 45 ºC until a 
clear solution was obtained. Drug solution was poured 
quickly in to 62.5 mL of water maintained at 20 ºC, under 
continuous stirring at 500 rpm with a propeller type agita-
tor. When fine crystals of naproxen begin to precipitate (5 
min), 12.5 mL of dichloromethane was added slowly drop 
wise, followed by 30 min stirring. Agglomerates obtained 
were separated from the solution by filtration and dried at 
60 ºC for 6 hours in an oven. The dried agglomerates were 
then stored in screw-capped jar in a desiccator.
Drug content
Spherical agglomerates (50 mg) were triturated with 
10 mL of water. Allowed to stand for 10 min with occa-
sional swirling and methanol was added to produce 100 
ml. 5 ml of this solution was mixed with equal volumes 
of methanol and phosphate buffer pH 7.4 to produce 100 
mL. Absorbance of the resulting solution was measured 
at 234 nm [6].
Melting point
Melting point of naproxen crystals was determined 
by placing the drug filled capillary tubes in digital melting 
point apparatus (Polmon, Hyderabad, India). Melting point 
was noted and compared with the pure drug.
Differential Scanning Calorimetry (DSC)
To detect possible polymorphic transition during 
the agglomeration process, DSC studies were carried 
out by using differential scanning calorimeter (DSC 60, 
Shimadzu, Japan) with DuPont 9900 thermal analyzer. All 
accurately weighed samples (about 1 mg of naproxen or its 
Improved dissolution and micromeritic properties of naproxen from spherical agglomerates: preparation, in vitro and in vivo characterization 669
equivalent) were placed in sealed aluminum pans, before 
heating under nitrogen flow (20 mL/min) at a scanning rate 
of 10 ºC min-1, from 25 ºC to 250 ºC. An empty aluminum 
pan was used as reference.
X-ray analysis
X-Ray powder diffraction patterns were used to 
detect possible polymorphic transition during the crystal-
lization process. X-Ray powder diffraction patterns were 
obtained at room temperature using X’ Pert MPD diffrac-
tometer (Philips, Holland), with Cu as anode material and 
graphite monochromator, operated at a voltage of 40mA, 
45 kV. The samples were analyzed in the 2q angle range 
of 3-50 and the process parameters used were set as scan 
step size of 0.0170 (2q), scan step time of 51.0362 sec and 
time of acquisition of 1 h. 2q values were processed using 
multidimensional minimization programme to calculate 
cell volume, cell parameters and space grouping.
Scanning electron microscopy
The Scanning electron microscopic (Joel- LV-5600, 
USA, with magnification of 250 X) photographs were 
obtained to identify and confirm spherical nature and 
morphological characters of the agglomerates.
Surface topography
Tracings of spherical agglomerates were taken using 
Camera Lucida fixed to optical microscope (magnification 
45 X) (Paradkar et al., 2002) and were used to calculate 
circulatory factor (S) as S=P2/ (12.56XA), where A is area 
(cm2) and P is perimeter (cm). 
Micromeritic properties
Particle size of pure drug was determined by mi-
croscopic method using calibrated ocular micrometer and 
size of spherical agglomerates was determined by sieving 
method [8]. Apparent particle densities of agglomerated 
and pure drug were measured using a Pycnometer (Gay 
Lussac, India). Carr’s index was determined from pow-
der volumes at the initial stage and after 1250 tappings 
to constant volume (Electrolab, Mumbai). The angle of 
repose of agglomerated and pure drug was measured by 
fixed funnel method.
Crushing strength
Crushing strength of agglomerates was determined 
using modified Jarosz and Parrot’s mercury load cell 
method (Paradkar et al., 2002). It was carried out using a 
10 mL glass hypodermic syringe. The modifications in-
clude removal of the tip of the syringe and the top end of 
the plunger. The barrel was used as a hollow support and 
guide tube with close fitting to the plunger. A window was 
cut at the lower end of the barrel to facilitate placement 
of the agglomerate on the base platen. The plunger acted 
as a movable platen. It was set directly on the agglomer-
ate, positioned on the lower platen. Mercury was added 
to the plunger at a rate of 10 g/sec from a separating fun-
nel, from a fixed height. The total weight of mercury plus 
that of plunger required to break the agglomerate was the 
crushing strength (g).
Determination of residual solvents concentration
Residual water in spherical agglomerates was de-
termined using Karl Fischer (Polmon, Hyderabad, India) 
titrimeter, calibrated with sodium tartrate. Gas chroma-
tography (Shimadzu GC-14B chromatograph, Japan) was 
used to estimate residual Acetone and dichloromethane in 
spherical agglomerates (Piera Di Martino et al., 2000).
Solubility studies
The solubility of naproxen spherical agglomerates in 
water was determined by taking excess quantity of spheri-
cal agglomerates into screw- capped 50 mL glass vials. 
The vials were shaken for two hours on mechanical shaker 
(Nocent et al., 2001). The solution was filtered and anal-
ysed for drug content spectrophotometrically at 234 nm.
Dissolution studies of agglomerates
The dissolution of naproxen pure drug and spherical 
agglomerates sample was determined by using USP dis-
solution apparatus XXIV-Type II (Electro Lab, Mumbai, 
India). The dissolution medium used was 900 ml of phos-
phate buffer (pH 7.4).
The 5 mL of sample solutions were withdrawn at 
predetermined time intervals and then filtered. A volume of 
5 mL of phosphate buffer (pH 7.4) was replaced in the dis-
solution flask to maintain volume constant. The amount of 
dissolved naproxen in the sample solutions was analyzed 
spectrophotometrically at 234 nm.
In vivo evaluation of agglomerates
The naproxen agglomerates obtained were subjected 
to in vivo studies to assess their anti-inflammatory activity 
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and to screen for ulcerogenic potential, the major adverse 
effect caused by the naproxen.
Evaluation of anti-inflammatory activity
The anti-inflammatory activity of prepared naproxen 
agglomerates was evaluated by the carrageenan-induced 
rat hind paw edema method (Rao et al., 1994). The experi-
mental protocol was designed and approval of Institutional 
Animal Ethics Committee (IAEC) (Reg. No. 557/02/c/
CPCSEA) was obtained. Wistar strain male albino rats 
weighing between (150-200 g) were used. The animals 
were in a light controlled 12 hours cycle with free access 
to food and water. Animals were fasted overnight before 
experiment with free access to water (Lichtenberger et 
al., 2009). Anti-inflammatory activity of the naproxen ag-
glomerates was compared to the pure naproxen drug. Ani-
mals were divided into three groups of six animals each. 
Group I (control I) received water. Group II, (standard) re-
ceived 25 mg/kg pure naproxen and Group III received 25 
mg/kg naproxen agglomerates. After one hour, paw edema 
was induced by injecting 50 µL of 1% w/v carrageenan 
into the sub planar region of the left hind paw. Paw volume 
was determined after five hour in all groups. Difference 
in the paw volume, determined before and after injection 
of the edema-provoking agent indicated the severity of 
edema. One control group and reference group were used 
in this study. Volumes of right hind paw of controls and 
treated animals were measured with a plethysmometer and 
the percentage inhibition of inflammatory reaction was 
determined for each animal by comparison with control 
and calculated by the following formula.
where, V control = mean edema of rats in control group; V test 
= mean edema volume of rats in tested group
Assessment of ulcerogenic potential of naproxen 
agglomerates
Healthy Wistar strain male albino rats weighing be-
tween 150 – 200 g were used for the study and individually 
maintained under standard conditions (12 h light and dark 
cycles, 25 ± 22 oC and 35–60% humidity). The rats were 
fed with animal fed pellets and had free access to water.
The rats were divided into three groups each con-
taining 6 animals that are controlled (group-1), standard 
(group-2) and test group (group-3). Animals were kept 
under fasting with free access to water for 48 h before 
test. Group 1 received plain water, Group 2 received pure 
naproxen (25 mg/kg) and Group 3 received naproxen 
agglomerates (25 mg/kg) and was sacrificed after 6 h 
(Veerapur et al., 2004). Their stomachs were isolated 
and opened along the greater curvature, the mucosa was 
washed under slow running tap water and the number and 
size of ulceration was scored as per the method (Rao et al., 
1994). The contents were centrifuged at 3000 rpm for 10 
min. Total acidity and pH was analyzed from the decanted 
supernatant by using broad range pH paper.
Ulcer index
The washed stomach was fixed on a cork plate and 
the number and severity of the ulcers were measured using 
the scores (Kulkarni, 2002).
Severity Score:
0 = Normal colored stomach
0.5 = Red coloration
1 = Spot ulcer
1.5 = Hemorrhagic streaks
2 = Ulcers ≥ 3 but ≤5
3 = Ulcers > 5.
RESULTS AND DISCUSSION
Selection of solvent proportions for spherical 
agglomeration
Spherical agglomerates of naproxen were prepared 
by simple agglomeration technique using a three solvent 
system. It involves a good solvent, a poor solvent and 
bridging liquid. Selection of these solvents depends on 
miscibility of the solvents and the solubility of the drug 
in individual solvents. Accordingly different combina-
tions were tried by ternary phase diagram to produce 
optimum solvent system (Di Martino et al., 2000). The 
drug solubility and mutual miscibility of solvent systems 
are examined. Acetone, water and dichloromethane were 
selected as solvent system.
Acetone is miscible with water and dichlorometh-
ane. The ternary diagram is envisaged, to select the solvent 
composition. The points on the vertex correspond to a pure 
liquid; those on the sides correspond to a mixture of only 
two liquids. Since the presence of three liquids is neces-
sary (good solvent, bridging solvent and poor solvent) 
for spherical agglomeration, points on the sides of the 
triangle are excluded. 36 points remain for experiment. 
Each triangle in the ternary diagram was investigated for 
the agglomeration. The optimal ratio for spherical ag-
glomeration was selected as 25:62.5:12.5.
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Preparation of spherical agglomerates of 
naproxen
The proportions of acetone/water/dichloromethane 
were chosen for the study is 25/62.5/12.5 mL respectively. 
Agglomerates were formed by agitating the crystals in a 
liquid suspension and adding a bridging liquid, which pref-
erentially wets the crystal surface to cause binding. The 
addition of bridging liquid (dichloromethane) promotes 
the formation of liquid bridges between the drug crystals 
to form agglomerates.
To optimize naproxen spherical agglomeration by 
acetone/water/dichloromethane system, other process 
parameters were considered such as amount and mode 
of addition of bridging liquid, stirring speed and time, 
temperature.
The average diameter of agglomerates was found to 
increase with increasing amount of dichloromethane in the 
agglomeration medium due to excessive bridging liquid 
on the surface for coalescence.
Size of agglomerates is very much dependent on 
the degree of agitation. Due to agitation droplets will 
be formed in the agglomeration medium and it induces 
movement of droplets from in to out. The intensity 
of this internal circulation depends on the speed. At 
lower stirring rate (<400 r/min) reduces the possibility 
of obtaining agglomerates due to slow circulation of the 
droplets in the medium and slight collision between the 
droplets. At optimum speed (500 r/min) more compact 
and dense agglomerates were obtained. Higher speed 
(>600 r/min) induces agglomerate destruction due to more 
impact energy for collision due to increased turbulence 
resulting in formation of agglomerates with irregular 
shape.
The temperature of solvent system was found to 
have pronounced effect on the process of agglomeration. 
Agglomeration was not observed when the process was 
carried out at 10±3 oC. It could be due to reduced solubility 
of drug in the solvent system. When the temperature was 
increased to 45±3 oC very large agglomerates were pro-
duced due to enhanced solubility (Saturation of the drug 
in the medium). Optimum agglomeration was achieved at 
20±3 oC due to optimum solubility of the drug.
Addition of bridging liquid plays vital role in forma-
tion off agglomerates. When the bridging liquid was added 
at a time agglomerates were of irregular geometry which 
may be due to its localization and hence its unavailabil-
ity for efficient agglomeration. Drop wise addition with 
continuous agitation resulted in agglomerates of regular 
geometry which can be attributed to uniform distribution 
of bridging liquid.
Drug content
The drug content obtained was in the range of 
99.12±1.54%.
Melting point
The melting point of naproxen pure drug and ag-
glomerates was found to be in the range 150 ºC -155 ºC 
and was observed that there was no change in melting 
points of pure drug and agglomerates. Thus, formation 
of polymorphs was over ruled, as crystal habit will not 
change the melting point.
Differential scanning calorimetry (DSC)
DSC thermograms of pure and naproxen agglomer-
ates are illustrated in Figure 1. The DSC pattern of pure 
naproxen and agglomerates showed a sharp endothermic 
peak at 153 ºC corresponding to its melting point. Sharp 
melting point with flat base line, which indicated that the 
material was not affected by hydration, solvation, poly-
morphic transition and in addition there was no interaction 
of drug with solvents.
X-ray analysis
X-Ray powder diffraction (XRD) is a powerful 
technique for the identification of crystalline solid phase. 
Every crystalline solid phase has a unique XRD pattern, 
which can form the basis for its identification. XRD pattern 
in 2θ range showed the diffraction peaks, characteristic 
of naproxen in both pure and agglomerate forms Figure 
2, suggesting that crystallization did not cause any struc-
tural modifications. The slight differences in the relative 
intensities of their peaks at the respective 2θ values may be 
attributed to differences in the particle size or crystallinity 
of the sample. The disappearance of peaks in naproxen 
agglomerates at 32 ° and 46 ° was due to the markedly 
different crystal habits. Therefore the relative abundance 
of the planes exposed to the X-ray source would have been 
altered, producing the disappearance of peaks or variations 
in the relative intensities of the peak.
XPRD spectral data of pure naproxen and spheri-
cal agglomerates were showed similar peaks indicating 
that there was no structural alteration occurred due to the 
technique employed for preparing spherical agglomerates.
Scanning electron microscopy
The surface morphology and shape of the agglomer-
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ates were identified in scanning electron microscopy. The 
pure naproxen was in the form of plate like particles as 
appeared in Figure 4. Where as naproxen agglomerates 
prepared were having clusters of plate shaped particles, 
which are not that spherical but irregular in shape as shown 
in Figure 3. Upon high magnification it was further ob-
served that surfaces are not smooth and no liquid bridges 
found in between particles shown in Figure 4. Thus the 
produced clusters may not be spherical agglomerates, but 
bunches of plate like crystals. This cluster formation may 
be responsible for enhancement of flow property, packabil-
ity and drug release rate as observed in our investigation.
Surface topography
Agglomerates obtained were moderately spherical in 
shape with circularity factor ranging between 0.891 - 0.912 
(1 Indicates the spherical shape).
Micromeritic properties
The micromeritic properties like bulk density, tapped 
density, angle of repose and Carr’s index were determined 
and shown in Table I. The bulk and tapped densities of the 
spherical agglomerates were lower than the corresponding 
value of the pure sample, with the particle size and spheric-
ity being higher. The lower density is likely to be related 
to the intraparticle porosity and reduced bulk density of 
the treated samples indicates a greater porosity within the 
agglomerated particles. Carr’s index for agglomerates was 
found to be lower when compared to pure drug. This may 
be due to the formation of agglomerates. Fine particles 
having high surface to mass ratios are more cohesive than 
coarser particles, hence more influenced by gravitational 
force. Decreased values of Carr’s index for agglomerates 
indicate better packability, and that they might be suitable 
for direct tabletting. Flow properties of the agglomerates 
were reflected by angle of repose. It was found that angle 
of repose of agglomerates were decreased when compared 
to pure naproxen. Such decreased value indicates improve-
ment in flowability.
Lower densities of spherical agglomerates than 
the pure sample indicate better spherecity and porosity. 
Lower Carr’s index for agglomerates makes their pack-
A – naproxen pure drug, B – naproxen agglomerates
FIGURE 1 - Differential scanning calorimetric thermograms of naproxen and agglomerates DSC chromatogram clearly shows that 
pure drug (A) and spherical agglomerate obtained (B) showed melting range of 148-158 °C indicating that there was no chemical 
modification in the drug due to the method employed.
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FIGURE 2 - X-Ray diffraction spectra of naproxen and agglomerates
FIGURE 3 - SEM of A: naproxen pure drug, B: agglomerate, C: surface of the agglomerate. The powder was irregularly shaped 
(A) and spherical agglomerates were obtained after the successful completion of experiment (B). The surface of the spherical 
agglomerate (C) shows that the minute particles of the drug have agglomerated to give a spherical shape.
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ability better, and might be suitable for direct tabletting. 
Flow properties of the agglomerates were reflected by 
angle of repose, and a lower value shows improvement 
in flowability.
Crushing strength
The crushing strength of agglomerates was in the 
range of 105-110 g and was unaffected by the process 
variables.
Residual solvents concentration
The results of residual solvent concentration in 
naproxen agglomerates reported in Table II. According 
to Guideline for residual solvents Q3C (International 
Conference on Harmonization of Technical Requirements 
For Registration of Pharmaceuticals For Human Use), 
acetone and dichloromethane are class 3 class 2 solvents 
respectively (solvents with low toxic potential and sol-
vents should be limited), thus the limits of 5000 ppm and 
600 ppm are acceptable without justification. The results 
obtained for acetone and dichloromethane are largely 
below the tolerated limits.
The residual solvent concentration of acetone and 
dichloromethane (solvents with low toxic potential and 
solvents should be limited), obtained were largely below 
the tolerated limits according to ICH guidelines and thus 
the agglomerates are acceptable
Solubility studies
Spherical agglomerates showed distinct solubility 
pattern in water and buffer (pH 7.4 phosphate). It was 
noted that solubility of spherical agglomerates increased 
when compared with pure drug as shown in Table III. But, 
it was found that the solubility of naproxen was more in 
buffer than water which can be owed to its poor water 
solubility in lower pH.
Spherical agglomerates showed increased solubility 
in water and buffer (pH 7.4 phosphate) compared to pure 
drug. But, it was found that the solubility of naproxen was 
more in buffer than water which can be owed to its poor 
water solubility in lower pH.
Dissolution studies of agglomerates
The dissolution rate of pure naproxen is less than 
that of naproxen agglomerates. The reason for faster dis-
solution is good wettability of the agglomerates. After 
applying one way analysis of variance (ANOVA) it has 
been observed that there was significant difference (p < 
0.05) between the dissolution profiles of agglomerates 
when compared to pure sample.
In vivo evaluation of agglomerates
Anti-inflammatory activity and ulcerogenic poten-
tial were carried out for pure naproxen and agglomerates. 
Table IV shows the results of paw edema and percentage 
inhibition of carrageenan-induced paw edema in rats 
treated with pure naproxen and naproxen agglomerates. An 
extremely significant (p<0.001) inhibition of carrageenan 
induced paw edema was observed in animals treated with 
naproxen agglomerates in comparison with control during 
the entire 3 h duration of the study, significant (p<0.05) in-
TABLE I- Micromeritic properties of naproxen pure drug and 
agglomerates
Properties Pure Drug Agglomerates
Particle size (mm) 5-10 830 (Average 
particle size)
Flow rate (g/s) 5.42 ± 1.87 11.23 ± 0.93
Angle of repose 54 ± 1.35 46 ± 0.79
Tapped density (g/mL) 0.211 ± 0.24 0.349 ± 0.14
Bulk density (g/mL) 0.134 ± 0.128 0.237 ± 0.43
Carr’s index 36.492 32.09
Mechanical strength ( % ) - 0.974 ± 1.37
Values are average of 3 determinations (n = 3)
TABLE II- Residual solvent contents of naproxen agglomerates
Residual solvent
Concentration 
(ppm)
Concentration limit 
(ppm)*
Water 0.912 ± 0.23% -
Acetone (Class III) 4.2036 ± 1.458 5000
Dichloromethane 
(Class II)
3.561 ± 2.14 600
*As per ICH guide lines. Values are average of 3 determinations 
(n = 3)
TABLE III- Solubility Data of naproxen
Solubility medium Pure Drug Agglomerates
Water (% W/V) 0.00586 ± 1.031 0.01795 ± 0.93
7.4 Phosphate buffer 
(% W/V)
3.94 ± 0.18 7.71 ± 0.34
Values are mean ± standard deviation (n = 3).
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TABLE IV- Anti-inflammatory activity of pure naproxen and naproxen agglomerates
Group Treatment Time (h) Paw volume mean % Inhibition
Control Water 5 0.46 ---
Standard 25 mg/kg pure naproxen 5 0.28±1.36 39.13±2.16
Test 25 mg/kg naproxen agglomerates 5 0.16±2.57 65.21±2.85
Values are mean ± standard deviation (n = 3).
hibition of carrageenan induced paw edema was observed 
in animals treated with naproxen agglomerates in compari-
son with naproxen pure drug during the entire 5 h duration 
of the study. This may be due to increased dissolution of 
agglomerates over pure drug, leading to better absorption 
and onset of action of drug. There was no drastic change 
in gastric pH when treated with naproxen and naproxen 
agglomerates. No ulcers were observed and the colour of 
stomach was normal.
Paw edema and percentage inhibition of carrageen-
an-induced paw edema in rats show a significant inhibition 
(p<0.05) in animals treated with naproxen agglomerates 
due to increased dissolution of agglomerates over pure 
drug, leading to better absorption and onset of action of 
drug. Hence, agglomerates showed better anti-inflamma-
tory activity over the pure drug.
Therefore, the results of the in vivo studies clearly 
demonstrate that the naproxen agglomerates showed bet-
ter anti-inflammatory activity over the pure drug, thus 
confirming the better therapeutic efficacy of the naproxen 
agglomerates.
CONCLUSION
Naproxen agglomerates that were prepared by simple 
spherical crystallization technique exhibited improved mi-
cromeritic properties and dissolution rate. DSC and XRD 
study showed that there is no change in the crystal structure 
and polymorphism was not occurred. Due to the significant 
improvement of micromeritic properties, this technique 
may be used for formulation of naproxen tablets by direct 
compression method. The agglomerates were found to be 
having better anti-inflammatory activity in the rats when 
compared to pure drug due to improved solubility.
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